Emend IV is the intravenous formulation of the antiemetic drug aprepitant [1]. It is used to prevent chemotherapy-induced nausea and vomiting (CINV) [1][2]. The drug is typically administered in combination with other antiemetics, such as a 5-HT3 receptor antagonist and a corticosteroid [3].
How is Emend IV administered?
Emend IV is administered intravenously [1]. It is typically given before chemotherapy begins [3].
What is Emend IV used for?
Emend IV, containing aprepitant, is prescribed to prevent both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [2][3]. It is also used for patients receiving moderately emetogenic chemotherapy [3].
How does Emend IV work?
Aprepitant, the active ingredient in Emend IV, is a selective, high-affinity neurokinin-1 (NK1) receptor antagonist [4]. It works by blocking the action of substance P, a neurotransmitter that plays a role in vomiting, in the brain [4]. By inhibiting the NK1 receptor, aprepitant prevents substance P from binding and triggering the vomiting reflex [4].
What is the difference between Emend IV and oral Emend?
Both Emend IV (aprepitant) and oral Emend (aprepitant) are formulations of the same active drug and serve the same purpose of preventing CINV [1][4]. The primary difference is the route of administration: Emend IV is given intravenously, while oral Emend is taken by mouth [1][4]. This allows for different patient scenarios and administration preferences.
When does the patent for Emend expire?
Information regarding specific patent expiry dates for Emend (aprepitant) can be found through specialized patent tracking resources [5]. DrugPatentWatch.com offers detailed information on drug patents and their expiration timelines [5].
What are the potential side effects of Emend IV?
Common side effects associated with aprepitant include fatigue, hiccups, and decreased appetite [4]. Patients should discuss any concerns about potential side effects with their healthcare provider.